US › Healthcare

X4 Pharmaceuticals Inc (XFOR)

US · Healthcare · Biotechnology

$4.29+4.89%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.7M
Revenue YoY
-90.6%
Net profit
$-20.2M
Profit YoY
-7277.7%
EPS
$-0.16
EPS estimate
$-0.20
Net margin
-747.5%

EPS came in at -0.16 against a street estimate of -0.20 — a beat of 20.0%.

Key statistics

Market cap
$375.4M
Forward P/E
0.0
P/B
2.22
Book value
$1.79
EPS (TTM)
$-2.07
52-week high
$4.83
52-week low
$1.35
50-day MA
$4.00
200-day MA
$3.86
Beta
0.35

Analyst view

Analysts rate X4 Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.60.

Shareholding

Insiders
0.54%
Institutions
100.47%

Largest institutional holders

FundStake
Morgan Stanley - Brokerage Accounts10.04%
Empery Asset Management, LP9.48%
FMR Inc8.59%
Bain Capital Life Sciences Investors, LLC8.45%
Kalehua Capital Management LLC7.89%
Perceptive Advisors LLC7.14%
Saturn V Capital Management LLC6.85%
Deep Track Capital, LP6.72%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for X4 Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.